Funding

Pandorum Technologies

India · Biotech

Develops tunable, regenerative exosome therapies for tissue health, disease, and degeneration

Visit pandorum.comFunding history

Funding history

1 round · 1 with disclosed amounts
AnnouncedRoundAmountInvestors
Series B$18MAshish Kacholia — Role not disclosedAvinya Fund — Role not disclosedBurman Family — Role not disclosedGalentic Pharma — Role not disclosedNoblevast Advisory — Role not disclosedProtons Corporate — Role not disclosed

Investors

Ashish KacholiaSeries BAvinya FundSeries BBurman FamilySeries BGalentic PharmaSeries BNoblevast AdvisorySeries BProtons CorporateSeries B

Coverage

Feb 9, 2026Pandorum Technologies · Series B

Similar companies

Pathos AIClinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.$237M · Series E
Star TherapeuticsBiotechnology company discovering and developing antibody therapies for diseases with significant unmet need.$200M · Private financing
iCUREXKagoshima medical-device company developing chitosan hydrogel materials for wound care, including the syringe-delivered Kitosla CX dressing.¥140M · Series A first close: equity and debt
Sourcespandorum.com ↗